The Effect of Semaglutide on Bone Turnover in Patients With Increased Risk of Bone Fracture

NCT04702516 · Unknown status

Last updated 2026-05-28

This clinical trial is testing whether semaglutide, a medication, affects bone health in adults with osteopenia, a condition that increases the risk of bone fractures.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase1, Phase2

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 64 people Planned (estimated).

Who can join Ages 40–85 · all sexes Healthy volunteers accepted.

Timeline Started 2021-03 · est. completion 2022-08

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT04702516 ↗

Description as written by the study sponsor.

The hypothesis for this study is that the GLP-1Ra Semaglutide has a positive effect on the balance between build-up and degradation as well as the strength of the bones in men and women aged 40-85 years at increased risk of bone fractures. Treatment involves injection of Semaglutide 1.34 mg/ml once a week or corresponding volume of placebo once a week for 52 weeks. The effect will be measured by bone markers in blood samples, bone scans, bone tissue tests (bone biopsy), and direct bone strength measured by microindentation at the start and end of the study.

Treatments tested

Ozempic Drug

2 mg prefilled pen for subcutaneous injection, 0.25 mg for two weeks then 0.5 mg for two weeks and then 1 mg for another 48 weeks.
Placebo Drug

2 mg prefilled pen for subcutaneous injection, 0.25 mg for two weeks then 0.5 mg for two weeks and then 1 mg for another 48 weeks.

Main thing measured	Procollagen type 1 N-terminal propeptide (P1NP)
Sponsor	Morten Frost
Conditions studied	Osteopenia
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04702516 ↗